Protocol Ledger

NCT06878404 · Phase III · ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

Interventional Phase III clinical trial protocol NCT06878404 sponsored by Johnson & Johnson / Janssen in Immunology, Rheumatology, and Dermatology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2025-02-21 Enrollment: 552 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT06878404
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)552 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)1 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT06878404
Protocol FieldVerified Registry Value
NCT IdentifierNCT06878404
Consolidated Lead SponsorJohnson & Johnson / Janssen
Therapeutic Condition CohortImmunology, Rheumatology, and Dermatology
Clinical Trial PhasePhase III
Overall Recruitment StatusACTIVE NOT RECRUITING
Registered Enrollment552 participants (ACTUAL)
Registered Start Date2025-02-21
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Listed on NCT06878404
Hospital Research SiteLocationSite Profile
Altoona Center For Clinical ResearchDuncansville, PAOpen Hospital Dossier ->

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Johnson & Johnson across sibling Meru public-data platforms.

Search related sites and sponsors in the Interactive Directory, explore Immunology, Rheumatology, and Dermatology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI